Abstract
In a multicentre, double-blind, randomized study involving four general hospitals in Israel, the efficacy and safety of ceftriaxone 1 g/day i.v. was compared to that of 2 g/day i.v. in the treatment of moderate to severe community-acquired infections requiring hospitalization. Two hundred and twenty-two patients were enrolled; 112 received intravenous ceftriaxone 1 g/day, and 110 received 2 g/day. The two groups were matched demographically, and their mean APACHE II score (10 points) and mean duration of successful therapy (7 days) were identical. The sites of infection in the 1 g and 2 g groups respectively were lower respiratory tract in 57 versus 51 patients, urinary tract in 31 versus 40 patients, and soft tissue in 24 versus 19 patients. There were no significant differences in clinical outcome between the 1 g and 2 g groups, the outcome being cure in 91 % versus 86 % of patients, improvement in 3 % versus 3 % of patients, failure in 3 % versus 8 % of patients, and relapse in 3 % versus 3 % of patients. The findings of this study indicate that ceftriaxone 1 g/day is as effective as 2 g/day in the treatment of moderate to severe community-acquired infections. The low-dose form is a more economical means of treating these infections.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Brogden RN, Ward A: Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties and an update on its therapeutic use with particular reference to once-daily administration. Drugs 1988, 35: 609–614.
Cleeland R, Squires E: Antimicrobial activity of ceftriaxone. A review. American Journal of Medicine 1984, 7: 3–11.
Lockman DS, Trincher RC, Rissing JP: Ceftriaxone therapy for serious bacterial infections. Current Therapeutic Research 1984, 36: 574–581.
Theron EJ, Nel CJC: Treatment of septic burns with a third-generation cephalosporin (ceftriaxone). South African Medical Journal 1983, 64: 816–817.
Hoepelman IM, Rozenberg-Arska M, Verhoef J: Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infection. Lancet 1988, i: 1305–1309.
Tice AD: Once-daily ceftriaxone outpatient therapy in adults with infections. Chemotherapy 1991, 37: 7–10.
Brown R: Once daily ceftriaxone in the treatment of lower respiratory tract infections. Chemotherapy 1991, 37: 11–14.
Francioli P, Etienne J, Hoigne R, Thys JP, Gerber A: Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and outpatient treatment feasibility. Journal of the American Medical Association 1992, 267: 264–267.
Bradsher RW, Snow RM: Ceftriaxone treatment of skin and soft tissue infections in a once-daily regimen. American Journal of Medicine 1984, 77: 63–67.
Fraschini F, Braga PC, Falchi M, Gattei G, Scaglione F, Scarpazza G, Esposti D: Ceftriaxone therapy in otolaryngological and pulmonary infections. Chemotherapy 1986, 32: 200–204.
Brown RB, Sands M: One-gram intravenous ceftriaxone use in a large teaching hospital. Results in 250 adult patients. Current Therapeutic Research 1989, 46: 285–291.
Fraschini F, Braga PG, Scarpazze G, Scaglione F, Pignataro O, Sambataro G, Mariani C, Roviaro GC, Voroli F, Esposti G: Human pharmacokinetics and distribution in various tissues of ceftriaxone. Chemotherapy 1986, 32: 192–199.
Karachalios G, Georgiopoulos AN, Kanatakis S: Treatment of various infections in an outpatient practice by intramuscular ceftriaxone. Home parenteral therapy. Chemotherapy 1989, 35: 389–392.
Maesen FPV, Davies BI, Teengs JP: Ceftriaxone in acute purulent exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 1984, 14: 653–660.
Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II. A severity of disease classification system. Critical Care Medicine 1985, 13: 818–829.
Segev S, Rosen N, Pitlik D, Block C, Rubinstein E: Pefloxacin versus ceftazidime in therapy of soft tissue infections in compromised patients. Journal of Antimicrobial Chemotherapy 1990, 26: 193–198.
Abbate GF, Alagia I, Giaquinto E, Leonessa V, Savioli L, Altucci P, Caputi M, Guarino C, Micello E, Catena E: Treatment of lower respiratory infections with ceftriaxone and cefotaxime. Respiration 1986, 49: 222–230.
Gutensohn A, Bunz D, Frighetto L, Jewesson P: Outcome of a ceftriaxone/cefotaxime interchange programme in a major teaching hospital. Chemotherapy 1991, 37:15–21.
Baumgartner JD, Glauser MP: Single daily dose treatment of severe refractory infections with ceftriaxone. Archives of Internal Medicine 1983, 143: 1868–1873.
Mandell LA, Bergeron MG, Ronald AR, Vega C, Harding G, Saginur R, Feld R, Duperval R, Landis SJ, Miedzinski LJ, Marrie T, Lalonde RG, Brunton JL, Low DE, Van R: Once-daily therapy with ceftriaxone compared with daily multiple-dose therapy with ceftriaxone for serious bacterial infections. A randomised, double-blind study. Journal of Infectious Diseases 1989, 160: 433–441.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Segev, S., Raz, R., Rubinstein, E. et al. Double-blind randomized study of 1 g versus 2 g intravenous ceftriaxone daily in the therapy of community-acquired infections. Eur. J. Clin. Microbiol. Infect. Dis. 14, 851–855 (1995). https://doi.org/10.1007/BF01691490
Issue Date:
DOI: https://doi.org/10.1007/BF01691490